EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Membranous nephropathy—diagnosis and identification of target antigens

Sanjeev Sethi, Fernando C Fervenza

Nephrology Dialysis Transplantation · 27.03.2024 · 39 (4) · 600-606

DOI: 10.1093/ndt/gfad227 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 20.10.2023. Verfasst von Sanjeev Sethi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Department of Laboratory Medicine and Pathology, Mayo Clinic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. MN is characterized by subepithelial accumulation of immune complexes along the glomerular basement membrane. The immune complexes are composed of immunoglobulin G and a target antigen. PLA2R is the target antigen in approximately 60% of MN cases, and MN is traditionally classified as PLA2R-positive or PLA2R-negative MN. Over the last 7 years, additional target antigens have been identified, which have specific disease associations, distinctive clinical and pathologic findings, and therapeutic implications. The newly discovered target antigens include NELL1, EXT1/EXT2, NCAM1, SEMA3B, PCDH7, FAT1, CNTN1, NTNG1, PCSK6 and NDNF. To group all these antigens into a generic ‘PLA2R-negative’ MN group is imprecise and un-informative. We propose a logical approach for detection of the target antigen which includes (i) currently available serology-based testing to detect anti-PLA2R and anti-THSD7A antibodies; and (ii) kidney biopsy testing to detect the target antigens. Determination of the antigen on kidney biopsy can be done by immunohistochemistry or immunofluorescence studies. Alternatively, laser capture microdissection (LCM) of glomeruli followed by mass spectrometry (MS) can be used to identify a target antigen. LCM/MS has the advantage of being a one-stop test and is particularly useful for detection of rare target antigens. At the current time, while it is possible to detect the newer antigens by immunohistochemistry/immunofluorescence/LCM/MS, serology-based tests to detect serum antibodies to the new antigens are not yet available. It is critical that serology-based tests should be developed not just for accurate diagnosis, but as a guide for treatment. We review the current methodology and propose an algorithm for diagnosis and detection of target antigens in MN that may shape the current practice in the future. Membranous nephropathy (MN) results from accumulation of subepithelial immune complexes along the glomerular basement membrane.PLA2R is the most common target antigen, but newly discovered target antigens have filled the void of PLA2R-negative MN.MN associated with the newly discovered target antigens have distinctive clinical and pathologic findings, treatment and prognostic implications. These include NELL1, EXT1/EXT2, NCAM1, PCDH7, SEMA3B, CNTN1, FAT1, NDNF and PCSK6.Immunohistochemistry/immunofluorescence methodology is currently in use for detecting target antigens in kidney biopsy tissue, although we anticipate laser capture microdissection of glomeruli followed by mass spectrometry will become available soon.Serologic testing is currently available for only detecting antibodies to PLA2R and THSD7A. It is critical that serologic tests become available for detecting antibodies to the newly discovered antigens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, MembranousAdultHumansAntigen-Antibody ComplexAutoantibodiesKidney GlomerulusPrognosisReceptors, Phospholipase A2

Stichwörter der Autor:innen

IHCantibodiesantigensmass spectrometrymembranous nephropathy

Substanzen

Antigen-Antibody ComplexAutoantibodiesReceptors, Phospholipase A2

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.

Förderung

  • Department of Laboratory Medicine and Pathology
  • Mayo Clinic

Zitieren

APA

Sethi, S., & Fervenza, F. C. (2024). Membranous nephropathy—diagnosis and identification of target antigens. Nephrology Dialysis Transplantation, 39(4), 600-606. https://doi.org/10.1093/ndt/gfad227

Vancouver

Sethi S, Fervenza FC. Membranous nephropathy—diagnosis and identification of target antigens. Nephrology Dialysis Transplantation. 2024;39(4):600-606. doi:10.1093/ndt/gfad227

BibTeX
@article{Sethi2024,
  author = {Sethi, Sanjeev and Fervenza, Fernando C},
  title = {Membranous nephropathy—diagnosis and identification of target antigens},
  journal = {Nephrology Dialysis Transplantation},
  year = {2024},
  volume = {39},
  number = {4},
  pages = {600--606},
  doi = {10.1093/ndt/gfad227}
}
Kostenlos starten →